Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cancer Therapy Risk-Reduction With Intensive Systolic BP Management (CARISMA) - a Phase II Study

NCT04467021 is registered in ClinicalTrials.gov with ECOG-ACRIN Cancer Research Group as lead sponsor.

NCT NCT04467021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04467021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cancer Therapy Risk-Reduction With Intensive Systolic BP Management (CARISMA) - a Phase II Study
Lead sponsor
ECOG-ACRIN Cancer Research Group
Phase
Not applicable
Overall status
Active, not recruiting
Start date
October 29, 2020
Completion date
August 31, 2027
Enrollment
61 (actual)
Sites
25

Conditions

As the registry lists them; a condition with its own page is linked.

cardiovascular disorder, chronic kidney disease, metastatic renal cell carcinoma, metastatic thyroid gland medullary carcinoma, stage iv renal cell cancer ajcc v8, stage iv thyroid gland medullary carcinoma ajcc v8, stage iva thyroid gland medullary carcinoma ajcc v8, stage ivb thyroid gland medullary carcinoma ajcc v8, stage ivc thyroid gland medullary carcinoma ajcc v8